Metropolitan Life Insurance CO Relmada Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Jun 14, 2023	BUY	$18.3 - $37.02 $30,213 - $61,120	1,651 New	1,651 $61.1 Million
Q2 2022 Jun 20, 2023	BUY	$16.5 - $30.34 $27,241 - $50,091	1,651 New	1,651 $31,000
Q1 2022 Jun 20, 2023	BUY	$16.72 - $26.99 $27,604 - $44,560	1,651 New	1,651 $44,000
Q1 2022 Mar 30, 2023	SELL	$16.72 - $26.99 $50,377 - $81,320	-3,013 Reduced 64.6%	1,651 $44,000
Q1 2022 May 12, 2022	SELL	$16.72 - $26.99 $50,377 - $81,320	-3,013 Reduced 64.6%	1,651 $45,000
Q4 2021 Jun 21, 2023	BUY	$16.93 - $26.82 $78,961 - $125,088	4,664 New	4,664 $105,000
Q3 2021 Jun 21, 2023	BUY	$21.86 - $34.77 $101,955 - $162,167	4,664 New	4,664 $122,000
Q2 2021 Jun 21, 2023	BUY	$29.55 - $39.15 $137,821 - $182,595	4,664 New	4,664 $149,000
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $137,673 - $182,399	4,659 Added 93180.0%	4,664 $149,000
Q1 2021 Jun 26, 2023	BUY	$31.52 - $39.28 $147,009 - $183,201	4,664 New	4,664 $164 Million
Q1 2021 May 14, 2021	SELL	$31.52 - $39.28 $146,851 - $183,005	-4,659 Reduced 99.89%	5 $164,000
Q4 2020 Jun 22, 2023	BUY	$29.88 - $39.8 $139,360 - $185,627	4,664 New	4,664 $149,000
Q3 2020 Jun 26, 2023	BUY	$34.42 - $43.78 $160,534 - $204,189	4,664 New	4,664 $175,000
Q2 2020 Jun 26, 2023	BUY	$31.59 - $49.98 $147,335 - $233,106	4,664 New	4,664 $208,000
Q2 2020 Mar 30, 2023	BUY	$31.59 - $49.98 $147,335 - $233,106	4,664 New	4,664 $208,000
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $147,335 - $233,106	4,664 New	4,664 $209,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $77.8M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.